# Rentosertib Encyclopedia

This site is a general-public and AI-readable encyclopedia for rentosertib, Insilico Medicine's investigational oral TNIK inhibitor for idiopathic pulmonary fibrosis (IPF), from target discovery and generative chemistry through Phase III clinical-trial preparation.

## Core thesis

Rentosertib is one of the most transparent public examples of end-to-end AI drug discovery because the evidence trail includes:

- AI-prioritized disease target: TNIK (TRAF2- and NCK-interacting kinase), identified at the end of 2019 after Insilico’s GENTRL publication
- AI-designed novel small molecule: rentosertib, formerly ISM001-055 / INS018_055
- Preclinical fibrosis models
- Phase 0 and Phase I human safety/tolerability/PK evidence
- Randomized Phase IIa patient data
- Peer-reviewed publications in Nature Biotechnology, Nature Medicine and Journal of Medicinal Chemistry
- Supporting aging-biology and senomorphic literature
- Phase III transition/announcement materials

## Chronology note

Insilico published its Generative Tensorial Reinforcement Learning (GENTRL) proof-of-concept in *Nature Biotechnology* in 2019. The TNIK/IPF target-discovery campaign should be placed at the end of 2019, after that publication, followed by 2020 generative chemistry and candidate selection work.

## Fast facts

- Drug: rentosertib
- Aliases: ISM001-055, INS018_055
- Developer: Insilico Medicine
- Indication: idiopathic pulmonary fibrosis (IPF)
- Target: TNIK
- Modality: oral small-molecule inhibitor
- Platform: Pharma.AI, including PandaOmics/Biology42 and Chemistry42
- Phase IIa signal: 60 mg once daily showed mean FVC +98.4 mL at 12 weeks versus -20.3 mL for placebo, with manageable safety/tolerability
- Status in this kit: Phase III announcement preparation
- Guardrail: investigational drug; not approved; no claim of cure or proven anti-aging effect

## Key publications

1. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology. DOI: 10.1038/s41587-024-02143-0
2. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nature Medicine. DOI: 10.1038/s41591-025-03743-2
3. Discovery of Bis-imidazolecarboxamide Derivatives as Novel, Potent, and Selective TNIK Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry. DOI: 10.1021/acs.jmedchem.4c01580
4. AI-Driven Robotics Laboratory Identifies Pharmacological TNIK Inhibition as a Potent Senomorphic Agent. Aging and Disease. DOI: 10.14336/AD.2024.1492
5. Hallmarks of aging-based dual-purpose disease and age-associated targets predicted using PandaOmics AI-powered discovery engine. Aging. DOI: 10.18632/aging.203960
6. Drug discovery by AI trained on aging biology. Nature Aging. DOI: 10.1038/s43587-024-00615-1

## Recommended wording

Rentosertib is an investigational oral TNIK inhibitor for IPF discovered and designed with Insilico Medicine's end-to-end AI platform. Its target-discovery, molecule-design and clinical-development story is unusually transparent and peer-reviewed, making it a major benchmark for AI-originated therapeutics.

## Avoid saying

- Do not say rentosertib is approved.
- Do not say Phase III has succeeded.
- Do not say rentosertib cures IPF.
- Do not say rentosertib is a proven anti-aging drug or approved geroprotector.
- Do not imply aging-clock or senomorphic findings are registrational endpoints.


## 2026-07-07 public-encyclopedia update

- Retitled the site: **Rentosertib Encyclopedia: From Target Discovery and Generative Chemistry to Phase III Clinical Trials**.
- Reframed the site for general-public use rather than only media use.
- Added the supplied visual history slide at `assets/rentosertib-pre-phase3-history.jpg`.
- Added plain-English “What is rentosertib?” and pre-Phase III evidence-ladder sections.
- Retained guardrails: investigational drug; no claim of approval, cure, successful Phase III, or proven anti-aging effect.


2026-07-07 update: Replaced the internal working-draft release framing with the official Insilico Phase III press release: https://insilico.com/news/xmjsn4l091-insilico-initiates-phase-iii-clinical-tr. Added the missing Insilico case-study link: https://insilico.com/casestudy.

2026-07-07 update: Restored the visual-history section to the original supplied Insilico slide image as the source of truth, with explanatory cards around it.

2026-07-07 update: Password protection removed for public rentosertib.net launch; site should be served publicly.